Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vertex

Painkillers without the addiction? The new wave of non-opioid pain relief

Pharma firms are developing drugs that avoid the brain’s opioid receptors to minimise the risks of dependence and overdoses, but not all experts are convinced

The Guardian - UK

It's your last chance to buy one of our all-time favorite Shark upright vacuums in the Walmart sale – I'm a vacuum tester, and it's a seriously worthy upgrade

The Shark Vertex DuoClean PowerFin Upright Vacuum is now heavily discounted and brilliant for busy homes

Homes & Gardens

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

“We’ve never been limited to traditional categories” – Arc'teryx goes all in on technical mountain running shoes for 2025

2025 brings some exciting new technical runners from the Canadian brand, including a running shoe you can climb in

Advnture

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

Barchart

Stocks With Rising Composite Ratings: Vertex

Vertex saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 92 the day before.

Investors Business Daily

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

Salon

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Investors Business Daily

FDA approves new type of non-opioid pain medication in two decades

The new drug will be many times more expensive than a standard opioid option

The Independent UK

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

Investors Business Daily

£1.65m gene-editing therapy offers hope of cure for some blood disorder patients

The treatment uses gene-editing tool Crispr, which earned its inventors the Nobel Prize in chemistry in 2020.

The Independent UK

FDA approves new painkiller that shows promise and challenges of opioid alternatives

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids

The Independent UK

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Vertex Pharmaceuticals Earnings Preview: What to Expect

With Vertex Pharmaceuticals gearing up to release its fourth-quarter earnings next month, analysts predict a single-digit drop in profit.

Investors Business Daily

S&P 500 Winners Fortinet, Boston Scientific Lead 5 Stocks Near Buy Points

S&P 500 components Fortinet and Boston Scientific are among five stocks to watch near buy points as 2024 comes to a close.

Investors Business Daily

Dow Jones Futures Fall: Small Caps Lead As SoundHound Surges; Nvidia At Key Level

Small caps rose with the major indexes steady Thursday. Nvidia is at key levels. SoundHound, Rocket Lab and other heat stocks soared.

Investors Business Daily

Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?

Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.

Investors Business Daily

Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain.

Investors Business Daily

Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.

Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.

Fortune

20 innovative breakthroughs that will transform your health

We recognize some of the most staggering, game-changing, life-improving developments of the year.

Benzinga

Decoding 9 Analyst Evaluations For Vertex

During the last three months, 9 analysts shared their evaluations of Vertex (NASDAQ:VERX), revealing diverse outlooks from bullish to bearish.

Benzinga

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.

Barchart

Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.